Mitochondria as Potential Target in Disease Therapy
A special issue of Future Pharmacology (ISSN 2673-9879).
Deadline for manuscript submissions: closed (10 December 2022) | Viewed by 3280
Special Issue Editors
Interests: mitochondria; reactive oxygen species; antioxidants
Special Issues, Collections and Topics in MDPI journals
Interests: cardiac reperfusion damage; mitochondrial bioenergetics; signal transduction; mitochondrial permeability transition pore
Interests: mitochondrial function; bioenergetics; redox signaling; chronic kidney disease; metabolic reprograming and extracelular vesicles
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The current special issue is designated to publish original articles investigating mitochondria as a therapeutic target in diseases because relevance of the impairment in this organelle in metabolism, immunity, apoptosis, and signal transduction alterations.
Mitochondria are highly dynamic organelles that have a critical role in ROS production, cross talking between redox signaling and metabolic regulation, in cell death regulation and calcium homeostasis. Thus, mitochondria impairment plays a pivotal role in the genesis and development of acute and chronic injuries, triggering pathological pathways like inflammation, oxidative stress and fibrosis. Furthermore, recent use of mitochondrial target therapies has showed promising results in resolve or prevent different pathologies. Therefore, we invite investigators to submit an original research paper or review articles for publication in this Special issue. We are particularly interested in articles related to mitochondrial improvement in diseases such as metabolic diseases, cancer, kidney diseases, hepatic diseases, heart diseases, and more.
Prof. Dr. José Pedraza Chaverri
Prof. Dr. Cecilia Zazueta
Dr. Omar Emiliano Aparicio Trejo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mitochondrial dysfunction
- mitochondrial therapeutic targets
- mitochondria and redox signaling
- metabolic regulation and mitochondria
- chronic and acute disease and mitochondria
- mitochondrial regulation in inflammation and fibrosis
- cell death and calcium regulation by mitochondria
